Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Sponsor
Alliance for Clinical Trials in Oncology (Other)
Overall Status
Completed
CT.gov ID
NCT00006125
Collaborator
National Cancer Institute (NCI) (NIH)
76
1

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkin's lymphoma.

Condition or Disease Intervention/Treatment Phase
  • Drug: doxorubicin hydrochloride
  • Drug: topotecan hydrochloride
Phase 2

Detailed Description

OBJECTIVES:
  • Determine the response rate and time to progression in patients with relapsed or refractory intermediate or high grade non-Hodgkin's lymphoma treated with doxorubicin and topotecan.

  • Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.

Patients are followed every 6 months for 2 years and annually for the next 3 years.

Study Design

Study Type:
Interventional
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Study Start Date :
Jul 1, 2000
Actual Primary Completion Date :
Aug 1, 2006

Arms and Interventions

Arm Intervention/Treatment
Experimental: Doxorubicin + topotecan

Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression. Patients are followed every 6 months for 2 years and annually for the next 3 years.

Drug: doxorubicin hydrochloride

Drug: topotecan hydrochloride

Outcome Measures

Primary Outcome Measures

  1. Response rate [Up to 5 years]

Secondary Outcome Measures

  1. Time to progression [Up to 5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
DISEASE CHARACTERISTICS:
  • Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma of one of the following subtypes:

  • Follicular center lymphoma, grade 3

  • Diffuse large B-cell lymphoma

  • Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma

  • Burkitt's lymphoma

  • High grade B-cell lymphoma, Burkitt-like

  • Anaplastic large cell lymphoma, CD30+ cell type

  • Anaplastic large cell lymphoma, T-cell type

  • Anaplastic large cell lymphoma, null-cell type

  • Anaplastic large cell lymphoma, Hodgkin's like

  • Bidimensionally measurable disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:
Age:
  • Any age
Performance status:
  • Not specified
Life expectancy:
  • Not specified
Hematopoietic:
  • Absolute neutrophil count at least 1,500/mm3

  • Platelet count at least 100,000/mm3

Hepatic:
  • Bilirubin no greater than 2.0 mg/dL history of Gilbert's Disease

  • AST no greater than 2.5 times upper limit of normal

Renal:
  • Creatinine normal
Cardiovascular:
  • LVEF at least 45% by MUGA or echocardiogram
Other:
  • Not pregnant or nursing

  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:
Biologic therapy:
  • Not specified
Chemotherapy:
  • Greater than 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin)

  • No greater than 96 mg/m2 mitoxantrone

  • No greater than 400 mg/m2 prior doxorubicin or combined total doxorubicin and mitoxantrone

  • No prior camptothecins

  • No other concurrent chemotherapy

Endocrine therapy:
  • No concurrent hormonal therapy except steroids for adrenal failure or hormones given for nondisease conditions (e.g., insulin for diabetes)

  • No concurrent dexamethasone or other steroidal antiemetics

Radiotherapy:
  • Greater than 3 weeks since prior radiotherapy

  • No concurrent radiotherapy except whole brain irradiation for documented CNS disease

Surgery:
  • Not specified

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northeast Alabama Regional Medical Center Anniston Alabama United States 36207
2 Rebecca and John Moores UCSD Cancer Center La Jolla California United States 92093-0658
3 Veterans Affairs Medical Center - San Diego San Diego California United States 92161
4 UCSF Comprehensive Cancer Center San Francisco California United States 94115
5 Veterans Affairs Medical Center - San Francisco San Francisco California United States 94121
6 CCOP - Christiana Care Health Services Newark Delaware United States 19713
7 Lombardi Cancer Center Washington District of Columbia United States 20007
8 Walter Reed Army Medical Center Washington District of Columbia United States 20307-5000
9 Veterans Affairs Medical Center - Washington, DC Washington District of Columbia United States 20422
10 Broward General Medical Center Fort Lauderdale Florida United States 33316
11 Memorial Regional Hospital Comprehensive Cancer Center Hollywood Florida United States 33021
12 CCOP - Mount Sinai Medical Center Miami Beach Florida United States 33140
13 Florida Hospital Cancer Institute Orlando Florida United States 32804
14 Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center West Palm Beach Florida United States 33401
15 Veterans Affairs Medical Center - Chicago (Westside Hospital) Chicago Illinois United States 60612
16 University of Chicago Cancer Research Center Chicago Illinois United States 60637-1470
17 Louis A. Weiss Memorial Hospital Chicago Illinois United States 60640
18 West Suburban Center for Cancer Care River Forest Illinois United States 60305
19 Saint Anthony Medical Center Rockford Illinois United States 61108
20 Fort Wayne Medical Oncology and Hematology, Incorporated Fort Wayne Indiana United States 46885-5099
21 Hematology Oncology Associates of the Quad Cities Bettendorf Iowa United States 52722
22 Holden Comprehensive Cancer Center Iowa City Iowa United States 52242-1009
23 Baptist Hospital East - Louisville Louisville Kentucky United States 40207
24 Marlene and Stewart Greenebaum Cancer Center, University of Maryland Baltimore Maryland United States 21201
25 Veterans Affairs Medical Center - Baltimore Baltimore Maryland United States 21201
26 Dana-Farber Cancer Institute Boston Massachusetts United States 02115
27 University of Massachusetts Memorial Medical Center - University Campus Worcester Massachusetts United States 01655
28 Lakeland Medical Center - St. Joseph Saint Joseph Michigan United States 49085
29 Veterans Affairs Medical Center - Minneapolis Minneapolis Minnesota United States 55417
30 University of Minnesota Cancer Center Minneapolis Minnesota United States 55455
31 Veterans Affairs Medical Center - Columbia (Truman Memorial) Columbia Missouri United States 65201
32 Ellis Fischel Cancer Center - Columbia Columbia Missouri United States 65203
33 Barnes-Jewish Hospital Saint Louis Missouri United States 63110
34 Washington University School of Medicine Saint Louis Missouri United States 63110
35 University of Nebraska Medical Center Omaha Nebraska United States 68198-7680
36 CCOP - Southern Nevada Cancer Research Foundation Las Vegas Nevada United States 89106
37 Veterans Affairs Medical Center - Las Vegas Las Vegas Nevada United States 89106
38 Norris Cotton Cancer Center Lebanon New Hampshire United States 03756-0002
39 Cooper University Hospital Camden New Jersey United States 08103
40 Veterans Affairs Medical Center - Buffalo Buffalo New York United States 14215
41 Roswell Park Cancer Institute Buffalo New York United States 14263-0001
42 Elmhurst Hospital Center Elmhurst New York United States 11373
43 Queens Cancer Center of Queens Hospital Jamaica New York United States 11432
44 CCOP - North Shore University Hospital Manhasset New York United States 11030
45 North Shore University Hospital Manhasset New York United States 11030
46 Memorial Sloan-Kettering Cancer Center New York New York United States 10021
47 Weill Medical College of Cornell University New York New York United States 10021
48 Mount Sinai Medical Center, NY New York New York United States 10029
49 State University of New York - Upstate Medical University Syracuse New York United States 13210
50 Veterans Affairs Medical Center - Syracuse Syracuse New York United States 13210
51 CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. Syracuse New York United States 13217
52 Veterans Affairs Medical Center - Asheville Asheville North Carolina United States 28805
53 Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina United States 27599-7295
54 NorthEast Oncology Associates Concord North Carolina United States 28025
55 Veterans Affairs Medical Center - Durham Durham North Carolina United States 27705
56 Duke Comprehensive Cancer Center Durham North Carolina United States 27710
57 Cape Fear Valley Health System Fayetteville North Carolina United States 28302-2000
58 Lenoir Memorial Hospital Cancer Center Kinston North Carolina United States 28503-1678
59 FirstHealth Moore Regional Hospital Pinehurst North Carolina United States 28374
60 New Hanover Regional Medical Center Wilmington North Carolina United States 28402-9025
61 CCOP - Southeast Cancer Control Consortium Winston-Salem North Carolina United States 27104-4241
62 Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina United States 27157-1082
63 Veterans Affairs Medical Center - Fargo Fargo North Dakota United States 58102
64 Arthur G. James Cancer Hospital - Ohio State University Columbus Ohio United States 43210-1240
65 Lifespan: The Miriam Hospital Providence Rhode Island United States 02906
66 Veterans Affairs Medical Center - Dallas Dallas Texas United States 75216
67 Green Mountain Oncology Group Bennington Vermont United States 05201
68 Vermont Cancer Center Burlington Vermont United States 05401-3498
69 Veterans Affairs Medical Center - White River Junction White River Junction Vermont United States 05009
70 Martha Jefferson Hospital Charlottesville Virginia United States 22901
71 Virginia Oncology Associates - Norfolk Norfolk Virginia United States 23502
72 MBCCOP - Massey Cancer Center Richmond Virginia United States 23298-0037
73 Oncology and Hematology Associates of Southwest Virginia, Inc. Roanoke Virginia United States 24014
74 St. Mary's Medical Center Huntington West Virginia United States 25701
75 Ministry Medical Group - Northern Region Rhinelander Wisconsin United States 54501
76 University of Puerto Rico School of Medicine Medical Sciences Campus San Juan Puerto Rico 00936-5067

Sponsors and Collaborators

  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)

Investigators

  • Study Chair: Nancy L. Bartlett, MD, Washington University Siteman Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00006125
Other Study ID Numbers:
  • CALGB-59906
  • U10CA031946
  • CLB-59906
  • CDR0000068140
First Posted:
Jan 27, 2003
Last Update Posted:
Jul 14, 2016
Last Verified:
Jul 1, 2016

Study Results

No Results Posted as of Jul 14, 2016